8-K - Connect Biopharma Holdings Limited | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Connect Biopharma reported 2025 full-year financial results with $55.5 million net loss, positive Phase 1 IV rademikibart data in asthma/COPD, and $20.2 million equity financing extending cash runway into second half of 2027.

Key Takeaways

1Positive topline Phase 1 data: IV rademikibart showed rapid FEV1 improvements of ≥200 mL in 15 minutes in asthma/COPD patients, maintained through Day 29.

2Phase 3 AD results by Simcere: rademikibart achieved rapid, durable efficacy in ~90% of patients, presented at AAD 2026.

3Ongoing Phase 2 Seabreeze STAT studies in acute asthma/COPD exacerbations; topline data expected mid-2026.

4$20.2 million private placement of 6,130,000 shares at $3.25/share, closing March 31, 2026, net of $1.6 million fees.

5Cash position $44.3 million as of Dec 31, 2025, sufficient into H2 2027 post-financing.

6FY2025 net loss $55.5 million ($1.00/share) vs $15.6 million ($0.28/share) in 2024; R&D expense up to $37.8 million.

Current Report Details

Event Type

Financial Results

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934,

Financial Results

9.01

Financial Statements and Exhibits. (d) Exhibits Exhibit No.: 99.1 | Description: Press Release of the Company, dated March 31 , 202 6 Exhibit No.: 104 | Descrip

Exhibits Only

Source Document

Results of Operations

Fiscal Year Ended December 31, 2025

Metric	Value	Prior Period
License and collaboration revenues	$64.00	$26.0K
Research and development expense	$37.8K	$29.3K
General and administrative expense	$20.3K	$19.2K
Net loss	$55.5K	$15.6K
Net loss per share	$-1.00	$-0.28

Exhibits (2)

8-K

99.1

EX-99.1